Dexmedetomidine and Esmolol Early Post Operative Cognitive Dysfunction
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine is a highly selective α2adrenoceptor agonist recently introduced to
anesthesia that produces dose dependent sedation, anxiolysis, and analgesia (involving spinal
and supraspinal sites) without respiratory depression.
From a pharmacokinetic perspective,dexmedetomidine has a half life of nearly 2 hours,
duration of action of nearly 4 hour, and thus, a side effect profile that is shorter in
duration than clonidine.
Esmolol is a cardioselective beta₁ receptor blocker with rapid onset, a very short duration
of action (elimination half-life is approximately 9 minutes) , and no significant intrinsic
sympathomimetic or membrane stabilising activity at therapeutic dosages